Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/09/2025 ,inter alia, to consider and approve the meeting ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Welcure Drugs & Pharmaceuticals has rescheduled its Board Meeting from 25th September 2025 to 27th September 2025 due to non-availability of directors. The board will consider a Letter of Intent (LOI) from Telexcell Trade PTE LTD, Singapore, for a proposed acquisition of up to 25% equity stake in the company at an indicative price of ₹20 per share, which the company describes as a substantial premium over the prevailing market price. The board will also deliberate on initiating due diligence (legal, financial, regulatory), authorising negotiations for definitive agreements, and exploring shareholder approval through postal ballot or general meeting in line with SEBI, RBI, FEMA, and stock exchange requirements. The deal is positioned to support the company's growth in global pharmaceutical and chemical exports using Telexcell's international trade network.
The proposed acquisition at a premium price could be positive for existing shareholders if the deal is finalised, offering a potential floor on the stock. However, the transaction is still in early stages, subject to due diligence, definitive agreements, and regulatory/shareholder approvals, so significant uncertainty remains until concrete terms are announced.